Molecular docking and identification of G-protein-coupled receptor 120 (GPR120) agonists as SARS COVID-19 MPro inhibitors.

ABSTRACT: COVID-19 has become a pandemic, and any new drug for treating the disease could save millions of lives. Several drugs already in use for other diseases and medical conditions are repurposed for treating COVID-19 in an attempt to find treatment for the disease without spending research time on ADME TOX and other studies on side effects. In this exercise, the drugs repurposed are from antiviral, antibiotics, antiviral for HIV and HCV, anti-cancer, natural medicines, etc. Possible repurposing anti-diabetic GPR-120 agonists used as for SAR-CoV-2 is attempted in the study by carrying out docking of 68 GPR-120 agonists. Ten of these compounds were found to have docking scores -8.3 to -8.0, and the best docking score was observed for an arylsulfonamide and a biarylpropanoic acid belonging to GPR1

SUBMITTER: Mohan S 

PROVIDER: S-EPMC9289937 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature